Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.

Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C, Foster J, Francis-West P, Köster M, Hauser H, Layward L, Vessillier S, Annenkov A, Al-Izki S, Pryce G, Bolton C, Baker D, Gould DJ, Chernajovsky Y.

Expert Opin Drug Deliv. 2014 Jan;11(1):5-16. doi: 10.1517/17425247.2013.839655. Epub 2013 Sep 27.

PMID:
24073618
2.

Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.

Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, Chernajovsky Y.

Ann Rheum Dis. 2012 Jan;71(1):143-9. doi: 10.1136/annrheumdis-2011-200100. Epub 2011 Oct 13.

PMID:
21998117
3.
4.

A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints.

Mullen L, Adams G, Foster J, Vessillier S, Köster M, Hauser H, Layward L, Gould D, Chernajovsky Y.

Ann Rheum Dis. 2014 Sep;73(9):1728-36. doi: 10.1136/annrheumdis-2013-203513. Epub 2013 Jun 27.

PMID:
23813971
5.

In vitro- and in vivo-targeted tumor lysis by an MMP2 cleavable melittin-LAP fusion protein.

Holle L, Song W, Holle E, Wei Y, Li J, Wagner TE, Yu X.

Int J Oncol. 2009 Oct;35(4):829-35.

PMID:
19724919
6.
7.

Targeting cytokines to inflammation sites.

Adams G, Vessillier S, Dreja H, Chernajovsky Y.

Nat Biotechnol. 2003 Nov;21(11):1314-20. Epub 2003 Oct 5.

PMID:
14528315
8.

The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice.

Böttinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB.

Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5877-82.

9.

The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta.

Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE.

J Biol Chem. 1999 May 7;274(19):13586-93.

10.
11.
12.

Engineering, expression and renaturation of targeted TGF-beta fusion proteins.

Tuan TL, Cheung DT, Wu LT, Yee A, Gabriel S, Han B, Morton L, Nimni ME, Hall FL.

Connect Tissue Res. 1996;34(1):1-9.

PMID:
8835843
13.
14.

Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3.

Vessillier S, Adams G, Chernajovsky Y.

Protein Eng Des Sel. 2004 Dec;17(12):829-35. Epub 2005 Feb 11.

PMID:
15708865
15.

Molecular interactions that confer latency to transforming growth factor-beta.

Young GD, Murphy-Ullrich JE.

J Biol Chem. 2004 Sep 3;279(36):38032-9. Epub 2004 Jun 18.

16.

[Role of a latent soluble TNF receptor type I (hsTNFRI) fusion protein in targeted treatment of endometriosis].

Xiong ZF, Hu S, Wang ZH.

Zhonghua Yi Xue Za Zhi. 2010 Mar 23;90(11):768-71. Chinese.

PMID:
20627024
17.
18.
19.

A corneal epithelial inhibitor of stromal cell collagenase synthesis identified as TGF-beta 2.

Strissel KJ, Rinehart WB, Fini ME.

Invest Ophthalmol Vis Sci. 1995 Jan;36(1):151-62.

PMID:
7822142
20.

Supplemental Content

Support Center